Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 9456

1.

Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.

Zeitoun JD, Baron G, Vivot A, Atal I, Downing NS, Ross JS, Ravaud P.

Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31061. [Epub ahead of print]

PMID:
28929484
2.

Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.

Daher A, de Groot J.

Exp Neurol. 2017 Sep 15. pii: S0014-4886(17)30237-6. doi: 10.1016/j.expneurol.2017.09.006. [Epub ahead of print] Review.

PMID:
28923369
3.

Access to benznidazole for Chagas disease in the United States-Cautious optimism?

Alpern JD, Lopez-Velez R, Stauffer WM.

PLoS Negl Trop Dis. 2017 Sep 14;11(9):e0005794. doi: 10.1371/journal.pntd.0005794. eCollection 2017 Sep.

PMID:
28910299
4.

Biosimilars: Implications for Clinical Practice.

Rifkin RM, Peck SR.

J Oncol Pract. 2017 Sep;13(9_suppl):24s-31s. doi: 10.1200/JOP.2017.025734.

PMID:
28898593
5.

Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.

Ronquillo JG, Zuckerman DM.

Milbank Q. 2017 Sep;95(3):535-553. doi: 10.1111/1468-0009.12278.

PMID:
28895231
6.

Determinants of Market Exclusivity for Prescription Drugs in the United States.

Kesselheim AS, Sinha MS, Avorn J.

JAMA Intern Med. 2017 Sep 11. doi: 10.1001/jamainternmed.2017.4329. [Epub ahead of print]

PMID:
28892528
7.

An update on new and unique uses of botulinum toxin in movement disorders.

Jankovic J.

Toxicon. 2017 Sep 6. pii: S0041-0101(17)30276-3. doi: 10.1016/j.toxicon.2017.09.003. [Epub ahead of print]

PMID:
28888928
8.
9.

Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035).

Tartari F, Santoni M, Pistelli M, Berardi R.

Cancer Treat Rev. 2017 Aug 24;60:12-17. doi: 10.1016/j.ctrv.2017.08.005. [Epub ahead of print] Review.

PMID:
28863312
10.

Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.

Bell C, Anderson J, Ganguly T, Prescott J, Capila I, Lansing JC, Sachleben R, Iyer M, Fier I, Roach J, Storey K, Miller P, Hall S, Kantor D, Greenberg BM, Nair K, Glajch J.

J Pharm Pract. 2017 Jan 1:897190017725984. doi: 10.1177/0897190017725984. [Epub ahead of print]

PMID:
28847230
11.

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Folic acid.

Hofsäss MA, Souza J, Silva-Barcellos NM, Bellavinha KR, Abrahamsson B, Cristofoletti R, Groot DW, Parr A, Langguth P, Polli JE, Shah VP, Tajiri T, Mehta MU, Dressman JB.

J Pharm Sci. 2017 Aug 22. pii: S0022-3549(17)30571-3. doi: 10.1016/j.xphs.2017.08.007. [Epub ahead of print]

PMID:
28842299
12.

Mycoplasma genitalium: Accurate Diagnosis Is Necessary for Adequate Treatment.

Gaydos CA.

J Infect Dis. 2017 Jul 15;216(suppl_2):S406-S411. doi: 10.1093/infdis/jix104. Review.

PMID:
28838072
13.

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.

Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyani PS, He K, Zhao H, Yu J, Paciga M, Goldberg KB, McKee AE, Keegan P, Pazdur R.

Oncologist. 2017 Aug 23. pii: theoncologist.2017-0078. doi: 10.1634/theoncologist.2017-0078. [Epub ahead of print]

PMID:
28835513
14.

Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-Oncology Research.

Kidwell KM, Postow MA, Panageas KS.

Clin Cancer Res. 2017 Aug 23. pii: clincanres.1355.2017. doi: 10.1158/1078-0432.CCR-17-1355. [Epub ahead of print]

PMID:
28835379
15.

Recent Advances in Targeting ROS1 in Lung Cancer.

Lin JJ, Shaw AT.

J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30668-8. doi: 10.1016/j.jtho.2017.08.002. [Epub ahead of print] Review.

PMID:
28818606
16.

Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

Naci H, Smalley KR, Kesselheim AS.

JAMA. 2017 Aug 15;318(7):626-636. doi: 10.1001/jama.2017.9415.

PMID:
28810023
17.

Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements.

Zheng SY, Dhruva SS, Redberg RF.

JAMA. 2017 Aug 15;318(7):619-625. doi: 10.1001/jama.2017.9414.

PMID:
28810022
18.

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues.

Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, Mercuri E, Muntoni F, Sepodes B, Vroom E, Balabanov P.

Nucleic Acid Ther. 2017 Aug 10. doi: 10.1089/nat.2017.0682. [Epub ahead of print]

PMID:
28796573
19.

Duration of Eligibility Prior to Cochlear Implantation: Have We Made Any Progress?

Appelbaum EN, Yoo SS, Perera RA, Coelho DH.

Otol Neurotol. 2017 Oct;38(9):1273-1277. doi: 10.1097/MAO.0000000000001544.

PMID:
28796093
20.

FDA Fast Tracks Nonopioid Pain Medication.

Abbasi J.

JAMA. 2017 Aug 8;318(6):510. doi: 10.1001/jama.2017.10250. No abstract available.

PMID:
28787490

Supplemental Content

Loading ...
Support Center